NCT05937581 is a Phase 1 clinical trial of CSL040 in Complement-mediated Disorders, sponsored by CSL Behring.

Who is sponsoring NCT05937581?

NCT05937581 is sponsored by CSL Behring.

What drugs are being tested in NCT05937581?

Interventions in NCT05937581: CSL040, Placebo.

What condition does NCT05937581 study?

NCT05937581 studies Complement-mediated Disorders.

Is NCT05937581 still recruiting?

NCT05937581 is currently completed. Last updated 3 February 2026.

Last reviewed 2026-02-03 · How we verify

NCT05937581

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects

Completed Phase 1 Last updated 3 February 2026

What this trial tests

Phase 1 trial testing CSL040 in Complement-mediated Disorders in 62 participants. Completed in 4 December 2025.

Timeline

28 September 2023

Primary endpoint
4 December 2025

4 December 2025

Quick facts

Lead sponsor	CSL Behring
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	quadruple
Primary purpose	treatment
Enrollment	62
Start date	28 September 2023
Primary completion	4 December 2025
Estimated completion	4 December 2025
Sites	1 location across Australia

Drugs / interventions tested

CSL040 — full drug profile →
Placebo

Conditions studied

Complement-mediated Disorders — all drugs for Complement-mediated Disorders →

Sponsor

CSL Behring — full company profile →

Who can join

Adults 18 to 64, any sex, with Complement-mediated Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other CSL Behring trials

Trials by the same sponsor.

NCT07326592 — Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza · Phase 4 · not yet recruiting
NCT07224360 — Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) · Phase 2 · recruiting
NCT07332091 — Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary He · Phase 2 · recruiting
NCT07094087 — Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovasc · Phase 3 · recruiting
NCT07048262 — Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NC · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05937581 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CSL Behring
Last refreshed: 3 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05937581.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing